Press Release

Global Non-alcoholic Steatohepatitis (NASH) Treatment Market to Surge Due to High Demand for Effective Drugs

The global non-alcoholic steatohepatitis (NASH) treatment market size is projected to gain impetus from a rise in the incidence of diabetes. This information is provided in an upcoming report by Fortune Business Insights, titled, “Non-alcoholic Steatohepatitis Treatment Market Size, Share and Global Trend By Drug Class (PPAR agonists, FXR-bile acid axis, Anti-oxidants, GLP-1/DPP-4/SGLT-2 agent, Anti-inflammatory agents, Anti-fibrotic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026.”

Segmentation of the Non-alcoholic Steatohepatitis (NASH) Treatment Market

By Drug Class            

  • PPAR agonists
  • FXR-bile acid axis
  • Anti-oxidants
  • GLP-1/DPP-4/SGLT-2 agent
  • Anti-inflammatory agents
  • Anti-fibrotic
  • Others

By Distribution Channel      

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography           

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

 

Intercept Pharmaceuticals Submits New Drug Application to FDA for Obeticholic Acid

Intercept Pharmaceuticals, a biopharmaceutical company, based in the U.S., announced that it has submitted its New Drug Application (NDA) for obeticholic acid (OCA) to the FDA in September 2019. It is meant for the treatment of patients suffering from fibrosis because of NASH. OCA is the only therapy to meet the endpoint of a Phase 3 study in patients living with NASH. The company has asked for a Priority Review for the NDA. If approved, it would result in a six-month review period. The submission is based on the results from the Phase 3 Regenerate study in those affected by liver fibrosis due to NASH. Regenerate is a Phase 3, multicenter, randomized, placebo-controlled, and double-blind study that assesses the efficacy and safety of OCA on clinical outcomes in NASH affected patients.

More Trending Topics From Fortune Business [email protected]

Intrathecal Pumps Market

Non-alcoholic Steatohepatitis Treatment Market

Animal Biotechnology Market

Laparoscopic Surgical Procedures Market

Nootropics Market

EEG and EMG Equipment Market

Urgent Care Centers Market

Surgical Lasers Market

Companion Animal Healthcare Market

Animal Wound Care Market

Hyperbaric Oxygen Therapy (HBOT)Market

Acute Care Market

Joint Pain Injections Market

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close